Fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) is indicated for treating adults with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2–based regimens in the setting of metastasis.
Jennifer Akosa, PharmD/MBA Candidate 2020, and Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP
Advertisement
Articles by Jennifer Akosa, PharmD/MBA Candidate 2020, and Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP
Advertisement
Latest Updated Articles
Fam-trastuzumab Deruxtecan-nxki for HER2-Positive Unresectable or Metastatic Breast CancerPublished: May 13th 2020 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
Lower Baseline BMI Predicts Weight Loss At 6 Months With Liraglutide
2
Providers, Patients Show Favorable Perception of Remdesivir During COVID-19 Pandemic
3
PCV21 Shows Cost Effectiveness Compared With PCV15, PCV13, and PPSV23
4
